BIO-B BIO-RAD LABORATORIES, INC.

NEUTRAL Impact: 4/10 8-K
Horizon months Filed Apr 24, 2026 Processed 1mo ago SEC 0000012208-26-000024
8-K context-dependent: Items 5.02
Latest settled — T+20d
BIO-B ▼ -10.69% at T+20d
NEUTRAL call ✗ call lost -10.69% · α vs SPY -15.65% · entry $299.45 → $267.43
Next anchor: T+60d in 5w
Last close $304.15 (close Jun 12) · +1.57% from $299.45 entry
Entry anchored
Apr 24, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.49%
$299.45
settled 7w ago
T+5d
0.00%
call 0.00% · α -0.40%
$299.45
settled 6w ago
T+20d
-10.69%
call -10.69% · α -15.65%
$267.43
settled 24d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Bio-Rad Laboratories amended its 2017 Incentive Award Plan, increasing the share reserve by 335,000 shares and extending the plan's expiration date to March 18, 2036. This amendment was approved by shareholders at the annual meeting, along with the re-election of all board nominees and ratification of auditors.

Actionable Insight

Monitor future equity grant practices and dilution levels as the increased share reserve provides more flexibility for executive compensation. The routine nature of these shareholder approvals suggests business continuity, but watch for any changes in executive compensation trends in upcoming filings.

Key Facts

  • Shareholders approved an amendment to increase the share reserve under the 2017 Incentive Award Plan by 335,000 shares
  • The plan's expiration date was extended by approximately two years to March 18, 2036
  • All nominated directors were re-elected at the annual meeting
  • Shareholders ratified KPMG LLP as independent auditors for 2026
  • The advisory vote on executive compensation was approved

Financial Impact

The plan amendment increases the share reserve by 335,000 shares for future equity compensation grants

share countequity compensationdilution

Risk Factors

  • Potential for increased share dilution from the additional 335,000 shares now available for grants
  • Governance risk if the expanded equity pool leads to excessive executive compensation

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000012208-26-000024
Document: bio-20260421.htm0000012208-26-000024
Document: 0000012208-26-000024-index-headers.html0000012208-26-000024
Document: 0000012208-26-000024-index.html0000012208-26-000024
Document: 0000012208-26-000024.txt0000012208-26-000024

US Market Status

Market Closed — Opens in 5h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access